Citations

Mayo Clinic

Showing 10 of 108522 citations.

Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer
Shah, Paras , Taylor, William R. , Negaard, Brianna J, Gochanour, Benjamin R. , Mahoney, Douglas W. , Then, Sara S., Devens, Mary E., Doering, Karen A. , Burger, Kelli N. , Nikolai, Brandon, Kaiser, Michael W., Allawi, Hatim T. , Cheville, John C. , Gettman, Matthew T., Gysbers, Brianna J , Doering, Karen A , Burger, Kelli N , Cheville, John C , Mahoney, Douglas W , Gysbers, Brianna J. , Foote, Patrick H. , Kisiel, John B.

Life | August 19, 2024 | Volume: 14 | Issue: 8 | Pages: 1024

10.3390/life14081024 | PMID 39202766 Get It

Introduction: Non-invasive assays are needed to better discriminate patients with prostate cancer (PCa) to avoid over-treatment of indolent disease. We analyzed 14 methylated DNA markers (MDMs) from urine samples of patients with biopsy-proven PCa relative to healthy controls and further studied discrimination of clinically significant PCa (csPCa) from healthy controls and Gleason 6 cancers. Methods: To evaluate the panel, urine from 24 healthy male volunteers with no clinical suspicion for PCa and 24 men with biopsy-confirmed disease across all Gleason scores was collected. Blinded to clinical status, DNA from the supernatant was analyzed for methylation signal within specific DNA sequences across 14 genes (HES5, ZNF655, ITPRIPL1, MAX.chr3.6187, SLCO3A1, CHST11, SERPINB9, WNT3A, KCNB2, GAS6, AKR1B1, MAX.chr3.8028, GRASP, ST6GALNAC2) by target enrichment long-probe quantitative-amplified signal assays. Results: Utilizing an overall specificity cut-off of 100% for discriminating normal controls from PCa cases across the MDM panel resulted in 71% sensitivity (95% CI: 49–87%) for PCa detection (4/7 Gleason 6, 8/12 Gleason 7, 5/5 Gleason 8+) and 76% (50–92%) for csPCa (Gleason ≥ 7). At 100% specificity for controls and Gleason 6 patients combined, MDM panel sensitivity was 59% (33–81%) for csPCa (5/12 Gleason 7, 5/5 Gleason 8+). Conclusions: MDMs assayed in urine offer high sensitivity and specificity for detection of clinically significant prostate cancer. Prospective evaluation is necessary to estimate discrimination of patients as first-line screening and as an adjunct to prostate-specific antigen (PSA) testing.
Drinking the disease: A family affected by arsenic in well water
Jegen, Dominika , Grygleski, Megan

Canadian Journal of Rural Medicine | August 19, 2024 | Volume: 29 | Issue: 3 | Pages: 132-134

10.4103/cjrm.cjrm_2_24 | PMID 39155636 Get It

Benefit of isolated surgical valve repair or replacement for functional tricuspid regurgitation and long-term outcomes stratified by the TRI-SCORE
Dreyfus, Julien , Juarez-Casso, Fernando M. , Eixerés‐Esteve, Andrea , Bohbot, Yohann, Bazire, Baptiste , Flagiello, Michele , Riant, Elisabeth , Mbaki, Yannick, Tomasi, Jacques , Sénage, Thomas , Eyharts, Damien , Doguet, Fabien , Viau, F , Eggenspieler, Florian , Heuts, Samuel , Galloo, Xavier , Benfari, Giovanni , Badano, Luigi P. , Enriquez-Sarano, Maurice, Bartko, Philipp E. , Lim, Pascal , Radu, Costin , Bernick, Jordan , Wells, George A. , Tribouilloy, Christophe , Iung, Bernard , Bonis, Michele De , Juarez-Casso, Fernando, Bazire, Baptiste , Flagiello, Michele , Riant, Elisabeth , Tomasi, Jacques , Senage, Thomas , Eyharts, Damien , Doguet, Fabien , Viau, Florence , Heuts, Samuel , Sardari Nia, Peyman , Heitzinger, Gregor , Marsan, Nina Ajmone , Maisano, Francesco , Topilsky, Yan , Michelena, Hector, Selton-Suty, Christine , Habib, Gilbert , Lavie-Badie, Yoan , Modine, Thomas , Chan, Vincent , Donal, Erwan , Wells, George , Tribouilloy, Christophe , De Bonis, Michele , Messika-Zeitoun, David , Enriquez-Sarano, Maurice , Benfari, Giovanni , Sala, Alessandra , Carnero, Manuel , Rahmouni, Kenza , Coisne, Augustin , Heitzinger, Gregor , Marsan, Nina Ajmone , Muraru, Denisa , Maisano, Francesco , Topilsky, Yan , Michelena, Héctor I. , Enriquez‐Sarano, Maurice , Bax, Jeroen J. , Selton‐Suty, Christine , Habib, Gilbert , Modine, Thomas , Chan, Vincent , Tourneau, Thierry Le , Donal, Erwan , Obadia, Jean‐François , Crestanello, Juan A. , Messika–Zeitoun, David

European Heart Journal | August 19, 2024 | Volume: 45 | Issue: 42 | Pages: 4512-4522

10.1093/eurheartj/ehae578 | PMID 39212387 Get It

Abstract Background and Aims Severe tricuspid regurgitation is associated with increased mortality rates, but benefit of its correction and ideal timing are not clearly determined. This study aimed to identify patient subsets who might benefit from the surgery. Methods In TRIGISTRY, an international cohort study of consecutive patients with severe isolated functional tricuspid regurgitation (33 centres, 10 countries), survival rates up to 10 years were compared between patients who underwent isolated tricuspid valve surgery (repair or replacement) and those conservatively managed, overall and according to TRI-SCORE category (low: ≤3, intermediate: 4–5, and high: ≥6). Results One thousand and two hundred seventeen were managed conservatively, and 551 underwent isolated tricuspid valve surgery (200 repairs and 351 replacements). TRI-SCORE distribution was 33% low, 32% intermediate, and 35% high. At 10 years, survival rates were similar between surgical and conservative management [41% vs. 36%; hazard ratio (HR) .97; 95% confidence interval (CI) .88–1.08, P = .57]. Surgery improved survival compared with conservative management in the low TRI-SCORE category (72% vs. 44%; HR .27; 95% CI .20–.37, P < .0001), but not in the intermediate (36% vs. 37%; HR 1.17; 95%CI .98–1.40, P = .09) or high categories (20% vs. 24%; HR 1.06; 95% CI .91–1.25, P = .45). Both repair and replacement improved survival in the low TRI-SCORE category (84% and 61% vs. 44%; HR .11; 95% CI .06–.19, P < .0001, and HR .65; 95% CI .47–.90, P = .009). Repair showed benefit in the intermediate category (59% vs. 37%; HR .49; 95% CI .35–.68, P < .0001) while replacement was possibly harmful (25% vs. 37%; HR 1.43; 95% CI 1.18–1.72, P = .0002). Conclusions Higher survival rates were observed with repair than replacement and benefit of intervention declined as TRI-SCORE increased with no benefit of any type of surgery in the high TRI-SCORE category. These results emphasize the importance of timely intervention and patient selection to achieve the best outcomes and the need for randomized controlled trials.
Modified Ex Vivo Renal Reconstruction to Facilitate Fenestrated-Branched Endovascular Repair of a Thoracoabdominal Aortic Aneurysm
Stutz, Jack , Lima, Guilherme Baumgardt Barbosa , Huang, Ying , Mendes, Bernado C., Macedo, Thanila A. , Oderich, Gustavo S. , Lima, Guilherme B , Oderich, Gustavo S

Journal of Endovascular Therapy | August 19, 2024 | Volume: 33 | Issue: 1 | Pages: 514-519

10.1177/15266028241270690 | PMID 39155603 Get It

Purpose: To report the use of modified ex vivo renal artery (RA) reconstruction in a patient with 2 small right RAs (RRAs) in anticipation of planned fenestrated-branched endovascular aortic repair (FB-EVAR) of thoracoabdominal aortic aneurysm (TAAA). Case Report: A staged hybrid repair was utilized in a patient with Extent II TAAA involving celiac axis (CA), superior mesenteric artery (SMA), single left RA (LRA), and 2 small (<3 mm) RRAs. The first-stage operation consisted of hepato-renal bypass using modified ex vivo renal reconstruction with single end-to-end anastomosis to both RAs using a saphenous vein graft. A second stage FB-EVAR was performed using patient-specific manufactured stent-graft with 3 fenestrations for the CA, SMA, and LRA 6 weeks later. The patient recovered with no complications. At 4 years, the patient had widely patent hepato-renal bypass and target vessels with normal renal function. Conclusion: The use of adjunctive hybrid procedures may optimize or facilitate FB-EVAR. In this patient, salvage of 2 small RAs was not ideally suited for branch stenting but was possible using modified ex vivo RA reconstruction with preservation of kidney parenchyma and function. Clinical Impact This case report illustrates a hybrid approach to overcome one of the most frequent limitations to total endovascular incorporation of renal arteries, eg small diameter, early bifurcation and multiple vessels. The modified ex vivo technique allows meticulous renal artery reconstruction without the deleterious effect of warm ischemia and without the cumbersome reconstruction of ureter and vein that is needed with traditional on table ex vivo auto transplantation. The technique is used in a minority of cases and adds the morbidity of open approach. Case selection is of paramount importance.
31‐GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort
Pazhava, Ani , Jing, Frank Z. , Pittelkow, Mark R. , Kim, Yong-Hun , Jing, Frank Z

International Journal of Dermatology | August 18, 2024 | Volume: 64 | Issue: 3 | Pages: 563-570

10.1111/ijd.17440 | PMID 39154363 Get It

AbstractBackgroundCutaneous melanoma (CM) is a significant health concern because of its high metastatic potential. Gene Expression Profile (GEP) testing, particularly the 31‐GEP test (DecisionDx‐Melanoma), has been increasingly used for risk stratification in CM patients. This study aimed to evaluate the clinical utility and performance of the 31‐GEP test in a real‐world setting.MethodsPatients with CM who underwent 31‐GEP testing from August 2014 to August 2022 at our institution were identified through searches of electronic health records. The study analyzed the influence of 31‐GEP testing on clinical decision‐making related to sentinel lymph node biopsy (SLNB), medical oncology referral, and postdiagnosis surveillance. Kaplan–Meier curves and Cox proportional hazard models were used to elucidate the test's performance, focusing on relapse‐free survival (RFS) and melanoma‐specific survival (MSS).ResultsThe study included 65 CM patients. Dermatologists ordered more than 80% of 31‐GEP tests. In 81.5% of cases, 31‐GEP results did not alter standard clinical management. SLNB decisions were unaffected in 92% of patients with pre‐SLNB 31‐GEP results. Among patients with stage I‐IIA melanoma, 25% of those with high‐risk 31‐GEP results were referred to medical oncology. Contrary to expectations, the rate of nodal metastasis was higher in low‐risk than in high‐risk 31‐GEP cases. Survival analysis showed overlapping RFS and MSS curves between different 31‐GEP classes, suggesting limited prognostic value.ConclusionsThe 31‐GEP test has a limited impact on clinical management decisions and shows limited prognostic value.
Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension
Burger, Charles D. , Tang, Wenze , Tsang, Yuen , Panjabi, Sumeet , Burger, Charles

Pulmonary Circulation | August 18, 2024 | Volume: 14 | Issue: 3 | Pages: No page available

10.1002/pul2.12415 | PMID 39157055 Get It

AbstractSelexipag is an oral selective agonist of the prostacyclin receptor approved to treat adults with pulmonary arterial hypertension (PAH). Selexipag is initiated at a dose of 200 μg twice daily (bid) and usually titrated up by 200 μg bid weekly (per label) or more slowly (e.g., every other week in real‐world clinical practice) to the highest tolerated individualized dose (ID) ranging from 200 to 1600 µg bid. In the Phase 3 GRIPHON trial, selexipag delayed disease progression and reduced risk of PAH‐related hospitalization compared with placebo; the effect was consistent across three prespecified ID groups: low (200–400 µg bid), medium (600–1000 µg bid), and high (1200–1600 µg bid). This study evaluated patient outcomes across selexipag dose ranges in real‐world practice. Data were analyzed from 1186 US adult patients with PAH on selexipag from the Komodo closed‐claims database (2015‒2022). Of these, 634 (53.5%) patients completed titration and reached their selexipag ID (43.8% high ID, 29.8% medium ID, 26.3% low ID). Subsequently, 72.4% of patients in the low ID group had dose adjustments compared with 61.9% (medium ID) and 34.5% (high ID; standardized mean difference 0.63). There were no significant differences in patient outcomes, i,e, persistence (time to discontinuation) and risk of all‐cause and PAH‐related hospitalization across ID groups. The findings in this diverse, real‐world population of patients with PAH reinforced an individualized approach to the dosing scheme to maximize benefit‐risk and achieve the highest tolerated dose with selexipag similar to findings from the GRIPHON trial and other studies.
LET‐based approximation of the microdosimetric kinetic model for proton radiotherapy
Parisi, Alessio , Beltran, Chris , Beltran, Chris J , Parisi, Alessio , Furutani, Keith M. , Sato, Tatsuhiko

Medical Physics | August 17, 2024 | Volume: 51 | Issue: 10 | Pages: 7589-7605

10.1002/mp.17337 | PMID 39153222 Get It

AbstractBackgroundPhenomenological relative biological effectiveness (RBE) models for proton therapy, based on the dose‐averaged linear energy transfer (LET), have been developed to address the apparent RBE increase towards the end of the proton range. The results of these phenomenological models substantially differ due to varying empirical assumptions and fitting functions. In contrast, more theory‐based approaches are used in carbon ion radiotherapy, such as the microdosimetric kinetic model (MKM). However, implementing microdosimetry‐based models in LET‐based proton therapy treatment planning systems poses challenges.PurposeThis work presents a LET‐based version of the MKM that is practical for clinical use in proton radiotherapy.MethodsAt first, we derived an approximation of the Mayo Clinic Florida (MCF) MKM for relatively‐sparsely ionizing radiation such as protons. The mathematical formalism of the proposed model is equivalent to the original MKM, but it maintains some key features of the MCF MKM, such as the determination of model parameters from measurable cell characteristics. Subsequently, we carried out Monte Carlo calculations with PHITS in different simulated scenarios to establish a heuristic correlation between microdosimetric quantities and the dose averaged LET of protons.ResultsA simple allometric function was found able to describe the relationship between the dose‐averaged LET of protons and the dose‐mean lineal energy, which includes the contributions of secondary particles. The LET‐based MKM was used to model the in vitro clonogenic survival RBE of five human and rodent cell lines (A549, AG01522, CHO, T98G, and U87) exposed to pristine and spread‐out Bragg peak (SOBP) proton beams. The results of the LET‐based MKM agree well with the biological data in a comparable or better way with respect to the other models included in the study. A sensitivity analysis on the model results was also performed.ConclusionsThe LET‐based MKM integrates the predictive theoretical framework of the MCF MKM with a straightforward mathematical description of the RBE based on the dose‐averaged LET, a physical quantity readily available in modern treatment planning systems for proton therapy.
Definite benefits of GLP-1 receptor agonists: what is the risk of gastroparesis and lung aspiration?
Camilleri, Michael

Gut | August 17, 2024 | Volume: 74 | Issue: 3 | Pages: 342-345

10.1136/gutjnl-2024-333036 | PMID 39153846 Get It

Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?
Simadibrata, Daniel Martin , Lesmana, Elvira , Lee, Yeong Yeh , Lee, Yeong Yeh

Expert Opinion on Investigational Drugs | August 17, 2024 | Volume: 33 | Issue: 10 | Pages: 1009-1018

10.1080/13543784.2024.2393868 | PMID 39152730 Get It

Barriers and facilitators of cardiovascular disease prevention services for women with prior gestational diabetes or hypertensive disorders of pregnancy in low-income, middle-income and high-income settings: a scoping review protocol
Quansah, Dan Yedu , Visintini, Sarah , O’Neill, Carley , Savard, Karine, Lewis, R., Coutinho, Thais , Mullen, Kerri‐Anne, Savard, Karine

BMJ Open | August 17, 2024 | Volume: 14 | Issue: 8 | Pages: e084212

10.1136/bmjopen-2024-084212 | PMID 39153794 Get It

Introduction Women with previous pregnancy-related cardiovascular risk indicators, including gestational diabetes mellitus (GDM) and hypertensive disorders of pregnancy (HDP), have an increased risk of future cardiovascular disease (CVD). Although CVD screening and preventive care beginning in the early postpartum period are recommended, certain barriers limit access to such services. We plan to conduct a scoping review of the literature to explore and summarise evidence on the barriers and facilitators of postpartum CVD preventive services in women with a history of GDM and HDP. Methods and analysis This scoping review will be conducted in line with the Arksey and O’Malley’s (2005) methodological framework and the Joanna Briggs Institute guidance for conducting a systematic scoping review and will follow the Evidence for Policy and Practice Information and the Coordinating Centre at the Institute of Education guidelines. The review results will be reported using the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist. We will search the following databases: Medline, Embase and CINAHL. We will conduct grey literature searches for registered dissertations and theses. Inclusion and exclusion criteria will be kept broad. Qualitative and quantitative studies published in English or French that investigated and reported percieved barriers or facilitators to postpartum CVD screening and preventive care among women with previous GDM and HDP will be included. Individual, interpersonal, organizational, and system level factors will be reported. Qualitative findings will be summarised narratively, and quantitative findings will be absorbed within the themes using the multisource synthesis method. Ethics and dissemination This review represents one objective of a larger project that was reviewed by the Ottawa Health Sciences Network Research Ethics Board (QI-184). We will disseminate knowledge emanating from this review through open-access publication, presentation/public forums on women’s cardiovascular health, women’s CVD prevention forums and social media. We will also present the findings of this review at the annual meeting of the Canadian Women’s Heart Health Alliance.